Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Equity Average (2022 - 2025)

Historic Equity Average for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$414.2 million.

  • Phathom Pharmaceuticals' Equity Average fell 9678.96% to -$414.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$414.2 million, marking a year-over-year decrease of 9678.96%. This contributed to the annual value of -$163.2 million for FY2024, which is 12113.73% down from last year.
  • Phathom Pharmaceuticals' Equity Average amounted to -$414.2 million in Q3 2025, which was down 9678.96% from -$372.1 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Equity Average high stood at $15.5 million for Q2 2022, and its period low was -$414.2 million during Q3 2025.
  • For the 4-year period, Phathom Pharmaceuticals' Equity Average averaged around -$145.1 million, with its median value being -$96.6 million (2023).
  • Its Equity Average has fluctuated over the past 5 years, first soared by 9948.24% in 2023, then plummeted by 24321849.71% in 2024.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Equity Average stood at -$50.6 million in 2022, then grew by 10.57% to -$45.3 million in 2023, then crashed by 386.78% to -$220.3 million in 2024, then crashed by 87.97% to -$414.2 million in 2025.
  • Its Equity Average stands at -$414.2 million for Q3 2025, versus -$372.1 million for Q2 2025 and -$296.0 million for Q1 2025.